Targeted delivery of gene-editing tools to eliminate HIV from the body
Official title: Lentivirus-like particle specific delivery of Cas12 ribonucleoprotein (RNP) to HIV reservoir cells in vivo for an HIV cure
Funded at Virginia Commonwealth University · NIH-11037998 · Data updated 2026-11-12
This study is exploring a new way to deliver gene-editing tools directly to HIV-infected cells, which could help remove the virus and improve treatment for people living with HIV.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virginia Commonwealth University NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | December 1, 2022 |
| Project end | November 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $836,927 |
| NIH project number | 5R01AI174301-03 |
| Project ID | NIH-11037998 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who have not responded adequately to standard antiretroviral therapies.
✕Less likely to help
Patients who are not infected with HIV or those who have advanced AIDS may not benefit from this research.
What this research studies
This research focuses on developing a novel method to deliver gene-editing tools specifically to cells infected with HIV. By using a specially designed lentivirus-like particle, the study aims to transport Cas12 ribonucleoprotein and mRNA directly to CD4-expressing cells, which are key targets for HIV. The approach seeks to excise HIV proviral DNA and the CCR5 co-receptor, potentially leading to a functional cure for HIV. Patients may benefit from this innovative strategy that aims to improve the precision and effectiveness of HIV treatment.
Why it matters
Potential benefit: If successful, this research could lead to a functional cure for HIV, significantly improving the lives of those living with the virus.
How similar studies have gone: Previous research has shown promise in using similar gene-editing approaches for HIV treatment, indicating potential for success in this novel application.
Where this research is happening
-
Virginia Commonwealth University
Richmond, United States Active
Researchers
- Principal investigator: Hu, Wenhui — Virginia Commonwealth University
- Study coordinator: Hu, Wenhui
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.